Home > Publications Database > LATE: Nicht jede Demenz ist Alzheimer – Diskussion einer neuen Krankheitsentität am Fallbeispiel : Zum aktuellen Stand der „limbic-predominant age-related TDP-43 encephalopathy“ (LATE). > print

001     154248
005     20240320115505.0
024 7 _ |a 10.1007/s00115-020-00922-z
|2 doi
024 7 _ |a pmid:32409844
|2 pmid
024 7 _ |a pmc:PMC7809002
|2 pmc
024 7 _ |a 0028-2804
|2 ISSN
024 7 _ |a 1433-0407
|2 ISSN
037 _ _ |a DZNE-2021-00109
041 _ _ |a German
082 _ _ |a 610
100 1 _ |a Görß, Doreen
|0 P:(DE-2719)2812583
|b 0
|e First author
|u dzne
245 _ _ |a LATE: Nicht jede Demenz ist Alzheimer – Diskussion einer neuen Krankheitsentität am Fallbeispiel : Zum aktuellen Stand der „limbic-predominant age-related TDP-43 encephalopathy“ (LATE).
260 _ _ |a Heidelberg
|c 2021
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1631283693_6054
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Limbic-predominant age-related TDP-43 (Transactivation response(TAR)-DNA-binding protein 43 kDa) encephalopathy (LATE) has recently been characterized as a distinct neuropathological entity within the spectrum of dementia. Neuropathological alterations in the sense of LATE were already previously described as a comorbidity to Alzheimer's disease (AD) and it has been diagnosed independently from AD pathology in autopsy studies since 2008. The framework of LATE would account for the pathogenetic impact of limbic TDP-43 proteinopathy as a driver of amnestic dementia, either together with comorbid typical AD changes or as a distinct feature. The LATE possibly explains divergent clinical observations and biomarker results in patients suffering from severe amnestic impairment without biomarker evidence of AD-related amyloid and tau alterations. Whether LATE represents a distinct neuropathological entity or is part of the spectrum of neurodegenerative diseases associated with TDP-43 is currently a matter of debate. Further studies on the role of TDP-43 in the development of amnestic dementia are urgently needed. Thus, the enrichment of an amnestic phenotype in amyloid-centered therapeutic drug studies bears the risk of higher rates of patients with TDP-43 comorbidity, which could hinder the proof of efficacy in such trials. This article presents the current state of the discussion on LATE and illustrates the concept and the clinical considerations with a case study.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a Dementia
|2 Other
650 _ 7 |a Proteinopathy
|2 Other
650 _ 7 |a SNAP
|2 Other
650 _ 7 |a TDP-43
|2 Other
650 _ 7 |a DNA-Binding Proteins
|2 NLM Chemicals
650 _ 7 |a TARDBP protein, human
|2 NLM Chemicals
650 _ 2 |a Alzheimer Disease: diagnosis
|2 MeSH
650 _ 2 |a Alzheimer Disease: epidemiology
|2 MeSH
650 _ 2 |a DNA-Binding Proteins: genetics
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a TDP-43 Proteinopathies: genetics
|2 MeSH
700 1 _ |a Kilimann, Ingo
|0 P:(DE-2719)2810394
|b 1
|u dzne
700 1 _ |a Dyrba, Martin
|0 P:(DE-2719)2810283
|b 2
|u dzne
700 1 _ |a Nitsch, Sascha
|b 3
700 1 _ |a Krause, Bernd
|b 4
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 5
|e Last author
|u dzne
773 _ _ |a 10.1007/s00115-020-00922-z
|g Vol. 92, no. 1, p. 18 - 26
|0 PERI:(DE-600)1462945-8
|n 1
|p 18 - 26
|t Der Nervenarzt
|v 92
|y 2021
|x 1433-0407
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/154248/files/115_2020_Article_922.pdf
856 4 _ |y OpenAccess
|x icon
|u https://pub.dzne.de/record/154248/files/115_2020_Article_922.gif?subformat=icon
856 4 _ |y OpenAccess
|x icon-1440
|u https://pub.dzne.de/record/154248/files/115_2020_Article_922.jpg?subformat=icon-1440
856 4 _ |y OpenAccess
|x icon-180
|u https://pub.dzne.de/record/154248/files/115_2020_Article_922.jpg?subformat=icon-180
856 4 _ |y OpenAccess
|x icon-640
|u https://pub.dzne.de/record/154248/files/115_2020_Article_922.jpg?subformat=icon-640
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/154248/files/115_2020_Article_922.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:154248
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2812583
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810394
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2810283
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2000026
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 2 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2021
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-12
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NERVENARZT : 2021
|d 2022-11-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2021-01-28
|w ger
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-12
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-12
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-12
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research Rostock /Greifswald
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1510100
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21